National Bank of Canada’s Recursion Pharmaceuticals RXRX Stock Holding History

National Bank of Canada’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.62K	Sell	1,837 -873,737	-100%	-$3.38M	﹤0.01%	2444
2025 Q4	$3.58M	Buy	875,574 +870,484	+17,102%	+$4.31M	﹤0.01%	944
2025 Q3	$24.8K	Sell	5,090 -55,510	-92%	-$292K	﹤0.01%	2111
2025 Q2	$307K	Sell	60,600 -9,800	-14%	-$48.1K	﹤0.01%	1525
2025 Q1	$372K	Buy	70,400 +53,100	+307%	+$387K	﹤0.01%	1387
2024 Q4	$117K	Buy	+17,300	New	+$116K	﹤0.01%	1727
2024 Q3	–	Sell	-200	Closed	-$1.49K	–	2999
2024 Q2	$1.49K	Sell	200 -1,000	-83%	-$8.72K	﹤0.01%	2454
2024 Q1	$10.3K	Sell	1,200 -1,950	-62%	-$21.7K	﹤0.01%	2176
2023 Q4	$31K	Buy	3,150 +1,500	+91%	+$10.7K	﹤0.01%	1907
2023 Q3	$11.7K	Buy	1,650 +1,500	+1,000%	+$15K	﹤0.01%	2160
2023 Q2	$1.12K	Hold	150	–	–	﹤0.01%	2539
2023 Q1	$1K	Buy	+150	New	+$1.19K	﹤0.01%	2529
2022 Q4	–	Sell	-1,000	Closed	–	–	2880
2022 Q3	$0	Sell	1,000 -2,000	-67%	-$20.3K	﹤0.01%	2860
2022 Q2	$24K	Buy	+3,000	New	+$20.1K	﹤0.01%	2019

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

National Bank of Canada's RXRX Position: Q1 2026 in Review

National Bank of Canada reduced its Recursion Pharmaceuticals (RXRX) stake by 100% in Q1 2026, selling an estimated $3.38M and leaving 1,837 shares worth $5.62K. The position accounts for ﹤0.01% of the portfolio, ranked #2444.

National Bank of Canada first reported a position in RXRX in Q2 2022 and has held it in 14 quarters since. The position peaked at $3.58M in Q4 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

National Bank of Canada held 1,837 shares of Recursion Pharmaceuticals worth $5.62K as of Q1 2026.
National Bank of Canada sold 873,737 Recursion Pharmaceuticals shares in Q1 2026, an estimated $3.38M.
Recursion Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2444 holding.
National Bank of Canada first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
National Bank of Canada's Recursion Pharmaceuticals position peaked at $3.58M in Q4 2025.
335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.